ArticleDrug safety2026
Challenges and Opportunities for Signal Detection During Public Health Emergencies: An Historical Re-evaluation of the Disproportionality Analysis of the ADR Reporting of Anti-COVID-19 Monoclonal Antibodies in Vigibase.
Article in Drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnti-spike monoclonal antibodies (mAbs) for early treatment of COVID-19 represented a significant improvement in the pharmacological management of the SARS-COV-2 pandemic, especially in early phases, but the continuous emergence of novel virus variants of concern (VoC) required a rapid and continuous benefit-risk assessment.
objectiveTo identify possible unexplored safety signals of anti-SARS-CoV-2 mAbs through disproportionality analysis using VigiBase, the World Health Organization (WHO) global pharmacovigilance database.
methodsWe conducted a disproportionality analysis of VigiBase (February 2020-December 2023). All de-duplicated individual case safety reports (ICSRs) for bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, regdanvimab, sotrovimab, and tixagevimab/cilgavimab were retrieved. Descriptive analyses of ICSRs and distribution of suspected adverse drug reactions across VoC-defined periods (Alpha, Delta, Omicron) were performed. Disproportionality analysis was conducted and reported in accordance with the READUS-PV guideline. Reporting odds ratios (RORs) with 95% confidence intervals (CI) were calculated at the MedDRA Preferred Term (PT) level, using the entire database as reference (excluding vaccines). Statistically significant drug-adverse reaction pairs included in the EMA Important Medical Event (IME) list and not described in the Summary of Product Characteristics (SmPC) were identified as potential safety signals.
resultsAmong 15,250 de-duplicated ICSRs, casirivimab/imdevimab accounted for the majority of reports (33.5%). Most cases involved female patients aged 45-64 years, predominantly reported from the Americas. Overall, 42,799 drug-adverse reaction pairs were identified, 33,948 (79.3%) of which were identified after filtering out, and 3047 (9.0%) were IMEs. Eighty-three unique drug-adverse reaction pairs had a statistically significant RORs, among which 56 (67.5%) were not listed in the SmPC. Bamlanivimab, as both monotherapy and in combination with etesevimab, showed increased reporting of several cardiac adverse events, including acute myocardial infarction (MI) and cardiac arrest. For tixagevimab/cilgavimab, disproportionality was found for acute MI (N = 6; ROR 12.7, 95% CI 5.7-28.4) and atrial fibrillation (N = 29; ROR 9.0, 95% CI 6.2-13.0). For regdanvimab, disproportionality emerged for hypokalemia (N = 13; ROR 5.8, 95% CI 3.4-10.1). For casirivimab/imdevimab, 5 out of 15 PTs were classified as adverse event of special interest: seizure-like phenomena (N = 8; ROR, 44.2; 95% CI 21.9-89.1), Guillain-Barré syndrome (N = 6; ROR 13.4, 95% CI 6.0-30.0), encephalopathy (N = 13; ROR 5.4, 95% CI 3.1-9.3), generalized tonic-clonic seizure (N = 9; ROR 5.0, 95% CI 2.6-9.7), and seizure (N = 57; ROR 3.1, 95% CI 2.4-4.0).
conclusionThis analysis identified potential cardiovascular and neurological safety signals, which will remain unexplored by longitudinal pharmacoepidemiologic studies due to the withdrawal of these agents from clinical use. Overall, this case study supported the full implementation of near real-time multimodal approaches to efficiently perform actionable signal management during public health emergencies.
Identifiers
42486961What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.